MA30816B1 - Agent prophylactique ou therapeutique pour le cancer - Google Patents

Agent prophylactique ou therapeutique pour le cancer

Info

Publication number
MA30816B1
MA30816B1 MA31823A MA31823A MA30816B1 MA 30816 B1 MA30816 B1 MA 30816B1 MA 31823 A MA31823 A MA 31823A MA 31823 A MA31823 A MA 31823A MA 30816 B1 MA30816 B1 MA 30816B1
Authority
MA
Morocco
Prior art keywords
cancer
protein
prophylactic
therapeutic agent
same
Prior art date
Application number
MA31823A
Other languages
English (en)
Inventor
Shuji Sato
Tsutomu Oshima
Tomofumi Kurokawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44083820&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30816(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/JP2006/320429 external-priority patent/WO2007043635A1/fr
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA30816B1 publication Critical patent/MA30816B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UN ANTICORPS MONOCLONAL HUMAIN DIRIGÉ CONTRE UNE PROTÉINE AYANT UNE SÉQUENCE D'ACIDES AMINÉS QUI EST LA MÊME OU ESSENTIELLEMENT LA MÊME QUE LA SÉQUENCE D'ACIDES AMINÉS DÉCRITE DANS LA SEQ ID NO : 1 OU 3, UN PEPTIDE PARTIEL DE LA PROTÉINE, OU UN SEL DE LA PROTÉINE. L'ANTICORPS MONOCLONAL HUMAIN EST UTILE COMME AGENT PROPHYLACTIQUE OU THÉRAPEUTIQUE POUR LE CANCER, PROMOTEUR DE L'APOPTOSE DE LA CELLULE CANCÉREUSE, INHIBITEUR DE LA PROLIFÉRATION DE LA CELLULE CANCÉREUSE, AGENT CYTOTOXIQUE POUR UNE CELLULE CANCÉREUSE QUI UTILISE UN MÉCANISME DE BIODÉFENSE VIA UNE RÉGION FC D'UN ANTICORPS, OU ÉQUIVALENTS.
MA31823A 2006-10-06 2009-04-27 Agent prophylactique ou therapeutique pour le cancer MA30816B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/JP2006/320429 WO2007043635A1 (fr) 2005-10-07 2006-10-06 Agent préventif/remède pour le cancer
ARP070101453A AR060362A1 (es) 2005-10-07 2007-04-04 Agente para prevenir / tratar el cancer
JP2007100876 2007-04-06

Publications (1)

Publication Number Publication Date
MA30816B1 true MA30816B1 (fr) 2009-10-01

Family

ID=44083820

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31823A MA30816B1 (fr) 2006-10-06 2009-04-27 Agent prophylactique ou therapeutique pour le cancer

Country Status (21)

Country Link
US (1) US20100008928A1 (fr)
EP (1) EP2067791A4 (fr)
JP (1) JPWO2008044754A1 (fr)
KR (1) KR20090078339A (fr)
CN (1) CN101541834A (fr)
AR (1) AR063153A1 (fr)
AU (1) AU2007307536A1 (fr)
BR (1) BRPI0717024A2 (fr)
CA (1) CA2666249A1 (fr)
CL (1) CL2007002879A1 (fr)
CO (1) CO6190538A2 (fr)
EC (1) ECSP099276A (fr)
IL (1) IL197389A0 (fr)
MA (1) MA30816B1 (fr)
MX (1) MX2009003126A (fr)
NO (1) NO20091783L (fr)
PE (1) PE20081456A1 (fr)
RU (1) RU2009117237A (fr)
TN (1) TN2009000090A1 (fr)
TW (1) TW200823235A (fr)
WO (1) WO2008044754A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011352205B2 (en) * 2010-12-31 2016-06-16 Bioatla, Llc Express humanization of antibodies
MX348578B (es) * 2011-08-04 2017-06-20 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
KR20150018604A (ko) * 2012-06-06 2015-02-23 온코메드 파마슈티칼스, 인크. 히포 경로를 조절하는 결합제 및 그의 용도
WO2014069681A1 (fr) * 2012-10-29 2014-05-08 인제대학교 산학협력단 Anticorps ciblant le cancer et composition permettant de prévenir ou de traiter le cancer en contenant
WO2014069682A1 (fr) * 2012-10-29 2014-05-08 인제대학교 산학협력단 Anticorps ciblant le cancer et composition permettant de prévenir ou de traiter le cancer en contenant
PT3258951T (pt) 2015-02-19 2020-08-18 Compugen Ltd Anticorpos anti-pvrig e métodos de utilização
US10550173B2 (en) 2015-02-19 2020-02-04 Compugen, Ltd. PVRIG polypeptides and methods of treatment
JO3620B1 (ar) * 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
LT3347379T (lt) 2016-08-17 2020-05-11 Compugen Ltd. Anti-tigit antikūnai, anti-pvrig antikūnai ir jų kombinacijos
EP3548071A4 (fr) 2016-11-30 2020-07-15 OncoMed Pharmaceuticals, Inc. Méthodes de traitement du cancer comprenant des agents de liaison à tigit
KR20200021474A (ko) 2017-06-01 2020-02-28 컴퓨젠 엘티디. 삼중 조합 항체 치료제
CA3106114A1 (fr) 2018-07-20 2020-01-23 Surface Oncology, Inc. Compositions anti-cd112r et procedes
EP4277904A1 (fr) 2021-01-15 2023-11-22 Seagen Inc. Conjugués anticorps-médicament immunomodulateurs
WO2022170002A1 (fr) 2021-02-03 2022-08-11 Seagen Inc. Composés et conjugués immunostimulateurs
WO2023161943A1 (fr) * 2022-02-28 2023-08-31 Nectin Therapeutics Ltd. Anticorps humanisés dirigés contre la nectine-2 et conjugués médicamenteux de ceux-ci
WO2023215740A1 (fr) 2022-05-06 2023-11-09 Seagen Inc. Conjugués anticorps-médicament immunomodulateurs
WO2024030577A1 (fr) 2022-08-03 2024-02-08 Seagen Inc. Conjugués anti-pd-l1-médicament immunostimulateurs
EP4321522A1 (fr) 2022-08-12 2024-02-14 Seagen Inc. Composés cytotoxiques et conjugués de ceux-ci

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
AU4228699A (en) 1998-06-03 1999-12-20 Northwestern University Cellular proteins which mediate herpesvirus entry
US20030129685A1 (en) * 1998-10-28 2003-07-10 Jian Ni 12 human secreted proteins
DE19852800C1 (de) 1998-11-16 2000-04-13 Univ Albert Ludwigs Freiburg Verfahren zur Herstellung von Antikörpern gegen ein Polypeptid, von dem die kodierende Nukleinsäure bekannt ist
US20030022279A1 (en) * 1999-06-14 2003-01-30 Fraser Christopher C. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
WO2002000677A1 (fr) 2000-06-07 2002-01-03 Human Genome Sciences, Inc. Acides nucleiques, proteines et anticorps
AU1305302A (en) 2000-10-05 2002-04-15 Immunex Corp Nectin polypeptides, polynucleotides, methods of making and use thereof
US20050112568A1 (en) 2001-06-05 2005-05-26 Lori Friedman Dgks as modifiers of the p53 pathwha and methods of use
EP1392111A4 (fr) 2001-06-06 2004-07-28 Regeneron Pharma Procede de ciblage de locus actifs sur le plan de la transcription
US20030084468A1 (en) 2001-09-05 2003-05-01 Economides Aris N. Methods of expressing transgenes
EP1571968A4 (fr) * 2002-04-16 2007-10-17 Genentech Inc Compositions et methodes permettant de diagnostiquer et de traiter une tumeur
AU2003295328A1 (en) 2002-10-02 2004-04-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1733743A4 (fr) * 2004-04-09 2007-06-27 Takeda Pharmaceutical Agents de prevention/remedes contre le cancer

Also Published As

Publication number Publication date
JPWO2008044754A1 (ja) 2010-02-18
BRPI0717024A2 (pt) 2014-03-11
AU2007307536A1 (en) 2008-04-17
CN101541834A (zh) 2009-09-23
MX2009003126A (es) 2009-04-06
CL2007002879A1 (es) 2008-06-27
CO6190538A2 (es) 2010-08-19
ECSP099276A (es) 2009-06-30
US20100008928A1 (en) 2010-01-14
CA2666249A1 (fr) 2008-04-17
EP2067791A4 (fr) 2009-11-25
TW200823235A (en) 2008-06-01
AR063153A1 (es) 2008-12-30
PE20081456A1 (es) 2008-11-27
IL197389A0 (en) 2011-08-01
RU2009117237A (ru) 2010-11-20
NO20091783L (no) 2009-07-01
TN2009000090A1 (en) 2010-08-19
AU2007307536A2 (en) 2009-04-30
WO2008044754A1 (fr) 2008-04-17
EP2067791A1 (fr) 2009-06-10
KR20090078339A (ko) 2009-07-17

Similar Documents

Publication Publication Date Title
MA30816B1 (fr) Agent prophylactique ou therapeutique pour le cancer
Kuriyan et al. X-ray structure of trypanothione reductase from Crithidia fasciculata at 2.4-A resolution.
AR113225A2 (es) Anticuerpo monoclonal aislado que se une específicamente a cxcr4 humano expresado sobre la superficie de una célula y que es capaz de inducir apoptosis de célula tumorales cxcr4⁺ in vivo
Juillerat-Jeanneret et al. Fibroblast activation protein-α in fibrogenic disorders and cancer: more than a prolyl-specific peptidase?
WO2021019246A1 (fr) Complexes peptidiques bicycliques hétérotandems
US20210101937A1 (en) Heterotandem bicyclic peptide complexes
EP3514167B1 (fr) Peptide de liaison à la thrombospondine 1
NZ610566A (en) Antibody purification
CN111819202A (zh) 释放区段及包含其的结合组合物
AR119080A1 (es) Proteínas multiespecíficas
JP2012512185A (ja) 膜１型マトリックス金属タンパク質阻害剤およびその使用
GEP20115324B (en) Tweak binding antibodies
Wong et al. Neuropeptide Y is a physiological substrate of fibroblast activation protein: Enzyme kinetics in blood plasma and expression of Y2R and Y5R in human liver cirrhosis and hepatocellular carcinoma
JP2020073562A (ja) 抗ｎｍｅ抗体
WO2018027329A1 (fr) CONJUGUÉS D'ANTAGONISTES DE TGF-β.
Amar et al. Clinical implications of compounds designed to inhibit ECM‐modifying metalloproteinases
US7374898B2 (en) Peptide inhibitors against seprase
KR20120084298A (ko) 펩티드 제거제
Kim et al. Identification of four new angiotensin I-converting enzyme inhibitory peptides from fermented anchovy sauce
Bissonnette et al. Proteomic analysis and immunodetection of the bovine milk osteopontin isoforms
US10905750B2 (en) GRP78 antagonist that block binding of receptor tyrosine kinase orphan receptors as immunotherapy anticancer agents
JP2011507498A5 (fr)
Glenn et al. Trypanocidal effect of α′, β′-epoxyketones indicates that trypanosomes are particularly sensitive to inhibitors of proteasome trypsin-like activity
Dahan et al. Dipeptidyl peptidase IV as a potential target for selective prodrug activation and chemotherapeutic action in cancers
RU2584572C2 (ru) Способ получения полипептида, конъюгированного с поли(этиленгликолевым) фрагментом, нуклеиновая кислота и слитый полипептид, предназначенные для применения в способе